Importantly, as disclosed in the most recent American Society of Hematology (ASH) abstracts in December of 2019, a number of novel TCEs targeting BCMA and CD20 are showing favorable and complete responses in myeloma and lymphoma patients, respectively (38–42). Here, TNFRSF17 is linked to plasma cell myeloma.